STAP Misconduct Investigator Steps Down

One of the RIKEN scientists investigating allegations of misconduct tied to stimulus-triggered acquisition of pluripotency work has resigned from the committee because of anonymous questions raised about his own research.

By | April 25, 2014

FLICKR, JOHN LESTERA RIKEN scientist investigating allegations of misconduct tied to Haruko Obokata and her colleagues’ stimulus-triggered acquisition of pluripotency (STAP) work has resigned from his post on the committee amidst alleged problems with his own published research, the Nature News blog reported. In a statement, molecular biologist Shunsuke Ishii from the RIKEN Advanced Science Institute said he chose to step down from the STAP misconduct investigation committee because of anonymous comments expressing doubt about data in two of his lab’s papers. In his statement, Ishii “deeply apologize[d]” for the inconvenience caused.

Earlier this month (April 1), the RIKEN committee reported evidence of data falsification and fabrication in the STAP papers. While a separate committee is working to determine whether the publications should be retracted and how Obokata might be disciplined for her alleged misconduct, the stem-cell researcher has stood by her results. “At this stage, considering the STAP cell discovery itself to be fabricated is a misunderstanding; I cannot possibly accept this,” Obokata said in an April 1 statement.

Now, Nature reported, Obokata’s lawyer said that questions about the validity of Ishii’s work are reason for a reinvestigation of the initial RIKEN report on STAP. Meanwhile, RIKEN will investigate claims related to Ishii’s research.

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. DNA Replication Errors Contribute to Cancer Risk
  3. Should Healthy People Have Their Exomes Sequenced?
    Daily News Should Healthy People Have Their Exomes Sequenced?

    With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.  

  4. Rethinking a Cancer Drug Target
    Daily News Rethinking a Cancer Drug Target

    The results of a CRISPR-Cas9 study suggest that MELK—a protein thought to play a critical role in cancer—is not necessary for cancer cell survival.

Business Birmingham